Emtricitabine Oral Solution shortage
Emtricitabine Oral Solution is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 22, 2026.
Gilead Sciences is stopping its emtricitabine oral solution (10 mg/mL), and this change is expected to be permanent. No other manufacturers of this liquid form are currently listed, so supply will not be available after March 2027.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Emtricitabine Oral Solution. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Jun 17, 2026Currently in shortage1 of 1 product affected.
-
Jun 17, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Gilead Sciences, Inc. 📞 800-445-3235 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Emtriva, Oral Solution, 10 mg/1 mL (NDC 61958-0602-1) | — | — | Product expected to be available until March 2027 | — |
These rows are manufacturer reports to the FDA for Emtricitabine Oral Solution — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Emtricitabine Oral Solution? options further down this page.
Why is Emtricitabine Oral Solution in shortage?
Gilead Sciences has reported to the FDA that they plan to permanently stop making their brand-name version of this medicine, Emtriva oral solution (10 mg/mL). The good news is that this isn't happening right away — Gilead has said the product is expected to remain available until March 2027, so there is still time before it goes away.
As for why Gilead made this decision, they didn't share a specific public reason with the FDA. This report covers only Gilead's product, so it speaks only to what's happening with their particular version of this oral solution.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Emtricitabine Oral Solution, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Emtricitabine Oral Solution?
Emtricitabine oral solution (10 mg/1 mL) is currently on the FDA drug-shortage list. I want to walk you through what this means so you can plan ahead with confidence.
The one strength of this product — 10 mg/1 mL — is listed with no available source on this report, and the status shows it is set to be discontinued. The maker reports it is expected to remain available until March 2027. Because this is a planned discontinuation, the supply problem may eventually be permanent, which makes a conversation with your prescriber the right next step before that date arrives.
Please keep in mind this information comes from national, manufacturer-reported FDA data, so it may not match what your local pharmacy actually has on its shelves today.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other manufacturers to see whether your strength can still be ordered while supply lasts.
- Because this product is planned for discontinuation, talk with your prescriber or pharmacist about a clinician-chosen plan for the future.
A manufacturer contact number is listed on this page for reference, though pharmacies usually make these calls for you. You have time to plan this thoughtfully.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Emtricitabine Oral Solution?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Emtricitabine Oral Solution is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Alternative dosage forms of Emtricitabine
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 1 productclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Emtriva 10 mg/mL | Gilead | 1 bottle | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Emtricitabine Oral Solution — that fall in the same broad treatment class (antivirals, hiv-specific, nucleoside analog, rti) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other anti-infective shortages
Emtricitabine Oral Solution shortage FAQs
Is Emtricitabine Oral Solution in shortage?
Which products are affected?
When will Emtricitabine Oral Solution be available again?
Can I still get Emtricitabine somewhere?
What should I do if I take Emtricitabine Oral Solution?
Still have a question about the Emtricitabine Oral Solution shortage?
Ask a pharmacist about this shortage →View Emtricitabine Oral Solution on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.